Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch + Lomb Corp (NYSE:BLCO) is reportedly considering a sale as it navigates separation issues from its parent company, ...

Bausch Health retained an 88 per cent shareholding in the eye care subsidiary after listing the group in 2022. But it planned ...

Bausch + Lomb (BLCO) stock will be in focus as company is exploring a sale to address concerns raised over its separation ...

Bausch+Lomb, valued at over $10 billion ... with nearly 60% coming from contact lenses and eye drugs. The potential sale is part of efforts to address concerns from creditors like Apollo Global ...

Company operates a contact lens manufacturing facility in Waterford where approximately 1,500 people are employed.

Consumer medical giant Bausch + Lomb may be preparing to sell off its eye care business, which would include contact lens ...

Bausch+Lomb ($BLCO), a contact lens supplier, is exploring a sale to address concerns raised by its lenders like Apollo ...

Bausch + Lomb is working with advisers from Goldman Sachs to test interest from possible buyers, the Financial Times reported ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...